Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 29,707 |
|
|||||
| News | - | ||||||
| Day High | 2.796 | Low High |
|||||
| Day Low | 2.61 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bio Path Holdings Inc | BPTH | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.1979 | -6.99% | 2.6321 | 12:12:28 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.77 | 2.61 | 2.796 | 2.83 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 234 | 29,707 | US$ 2.71 | US$ 80,650 | - | 2.3601 - 44.80 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 12:17:18 | 12 | US$ 2.6364 | USD |
Bio Path Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.79M | 678.80k | - | 0 | -16.08M | -23.69 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Bio Path News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BPTH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.65 | 2.88 | 2.3601 | 2.66 | 116,407 | -0.0179 | -0.68% |
| 1 Month | 4.23 | 7.6699 | 2.3601 | 4.16 | 4,393,682 | -1.60 | -37.78% |
| 3 Months | 9.30 | 9.9875 | 2.3601 | 4.28 | 1,574,993 | -6.67 | -71.70% |
| 6 Months | 13.176 | 13.80 | 2.3601 | 4.73 | 794,642 | -10.54 | -80.02% |
| 1 Year | 27.60 | 44.80 | 2.3601 | 10.64 | 1,153,851 | -24.97 | -90.46% |
| 3 Years | 119.20 | 172.398 | 2.3601 | 39.70 | 526,783 | -116.57 | -97.79% |
| 5 Years | 347.60 | 486.80 | 2.3601 | 92.72 | 526,811 | -344.97 | -99.24% |
Bio Path Description
| Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. |
